Average Score: TMC Life Sciences Berhad (Tmclife-Ku)

TMC LIFE SCIENCES BERHAD (TMCLIFE-KU)
Healthcare Services & Equip. / Health Providers & Svcs. / Health Facilities & Svcs. DETAILED STOCK REPORT
Report Date: 2021-Aug-25
Last Close Avg Daily Vol 52-Week High Trailing PE Annual Div ROE LTG Forecast 1-Mo Return
0.61 (MYR) 254,206 0.82 55.1 -- 2.1% -- -0.8%
2021 August 24 Market Cap 52-Week Low Forward PE Dividend Yield Annual Rev Inst Own 3-Mo Return
MALAYSIA Exchange
1.0B 0.47 -- 0.3% 184M 0.2% -4.7%
AVERAGE SCORE
NEUTRAL OUTLOOK: TMCLIFE's current score Score Averages
is relatively in-line with the market. Health Providers & Svcs. Group: 5.3 Mid Market Cap: 6.2
Healthcare Services & Equip. Sector: 5.4 FBM KLCI Index: 6.6
Average Score Trend (4-Week Moving Avg) Peers -6M -3M -1M -1W Current 1Y Trend
Positive IHH 6 6 6 8 7
TDM 3 4 4 5 6
Neutral KPJ 6 5 4 4 4
TMCLIFE 7 4 5 5 4
Negative
2018-08 2019-08 2020-08 2021-08
HIGHLIGHTS I/B/E/S MEAN

- The score for Tmc Life Sciences Berhad dropped to its 3-year
low of 4 this week. NA Mean recommendation from all analysts covering
0 Analysts the company on a standardized 5-point scale.
- The recent change in the Average Score was primarily due to a
decline in the Price Momentum component score.
Strong Strong
Sell Hold Buy
Sell Buy
PRICE AND VOLUME CHARTS

1-Year Return: 19.6% 5-Year Return: -34.8%
BUSINESS SUMMARY
TMC Life Sciences Berhad is a Malaysia-based investment holding company. The Company operates in the healthcare sector. The Company, through
its subsidiaries, provides multi-disciplinary tertiary healthcare services. The Company's subsidiaries include IVF Technologies Malaysia Sdn. Bhd.,
which is engaged in the provision of fertility services and operation of women's clinic; TMC Biotech Sdn. Bhd., which is engaged in provision of fertility
consultancy, laboratory and embryology services and research and development; TMC Lifestyle Sdn. Bhd., which is engaged in development,
marketing and management of healthcare programs; TMC Properties Sdn. Bhd., which is involved in property investment; TMC Care Sdn. Bhd., which
is engaged in the provision of pharmacy services and products; TMC Women's specialist Holdings Sdn. Bhd., which operates specialist holdings fertility
centers, and PT Tropicana Healthcare Indonesia, which is engaged in marketing and promoting of healthcare products.
Page 1 of 11
© 2021 Refinitiv. All rights reserved.
INDICATOR COMPONENTS
The AVERAGE SCORE combines the quantitative analysis of five widely-used investment decision making tools: Earnings,
Fundamental, Relative Valuation, Risk, and Price Momentum. A simple average of the underlying component ratings is normally
distributed to rank stocks on a 1-10 scale (10 being awarded to the most favorable). These factors may be evaluated differently using
alternative methodologies and the importance of individual factors varies across industries, market capitalization and investment styles.
Additional criteria should always by used to evaluate a stock.
Earnings Fundamental Relative Valuation Risk Price Momentum
PEER ANALYSIS Currency in MYR
PRICE MOMENTUM VALUATION FUNDAMENTAL ANALYSTS

Average Price 1-Mo 3-Mo 1-Yr Market Trailing Forward Dividend Net LTG I/B/E/S # of
Score Ticker (2021-08-24) Return Return Return Cap PE PE Yield Margin Forecast Mean Analysts
7 IHH 5.81 0.0% 12.4% 7.4% 50.4B 57.0 33.6 0.7% 6.5% -- Buy 18
7 TOPGLOV 3.85 -7.0% -26.8% -58.6% 31.2B 3.6 6.7 15.2% 48.7% 18.6% Hold 21
4 KPJ 1.06 1.9% 6.5% 26.9% 4.8B 53.0 23.0 1.1% 4.0% -- Buy 13
4 TMCLIFE 0.61 -0.8% -4.7% 19.6% 1.0B 55.1 -- 0.3% 8.7% -- -- --
6 TDM 0.26 2.0% -8.9% 6.3% 431M -- -- 2.0% -2.1% -- -- --
5 OPTIMAX 1.27 -0.8% -17.5% 62.8% 346M 37.2 27.6 -- 10.1% -- Hold 1
5 MGRC 2.20 18.3% 70.5% 315.1% 256M 13.3 -- -- -411.2% -- -- --
6 UCREST 0.32 -5.9% -26.4% 120.7% 193M 18.2 -- -- 45.1% -- -- --
5 LYC 0.35 9.5% 32.7% -11.5% 151M -- -- -- -46.3% -- -- --
NR SMILE 0.24 4.4% -4.1% -2.1% 59M 59.3 -- 1.4% 3.8% -- -- --
5.4 Average 1.60 2.2% 3.4% 48.7% 8.9B 37.1 22.7 3.5% -33.3% 18.6% Buy 13.3
PEER COMPANIES
IHH IHH Healthcare SMILE Smile-Link Healthcare Global
KPJ KPJ Healthcare TDM TDM
LYC LYC Healthcare TOPGLOV Top Glove Corp
MGRC Malaysian Genomics Resource UCREST UCrest
OPTIMAX Optimax Holdings
Page 2 of 11
EARNINGS Currency in MYR
This company does not currently meet the data Earnings Score Averages
requirements to calculate a score for this Health Providers & Svcs. Group: 4.0 Mid Market Cap: 5.5
component. Healthcare Services & Equip. Sector: 3.6 FBM KLCI Index: 5.8
Earnings Score Trend (4-Week Moving Avg) Peers -6M -3M -1M -1W Current 1Y Trend
KPJ 1 2 1 1 1
Neutral TDM NR NR NR NR NR
TMCLIFE NR NR NR NR NR
Negative
2018-08 2019-08 2020-08 2021-08
EARNINGS INDICATORS
Earnings Surprises Estimate Revisions Recommendation Changes
(33.3% weight) (33.3% weight) (33.3% weight)
IHH
IHH
IHH
KPJ
KPJ KPJ
TDM TDM TDM

TMCLIFE TMCLIFE TMCLIFE
Last 4 Quarters Last 4 Weeks Last 120 Days

# Positive Surprises (>2%) 0 # Up Revisions -- # Broker Upgrades 0
# Negative Surprises (<-2%) 0 # Down Revisions -- # Broker Downgrades 0
# In-Line Surprises (within 2%) 0 Avg Up Revisions --
Avg Surprise -- Avg Down Revisions --
HIGHLIGHTS PRICE TARGET

- Due to a lack of recent analyst activity, no Earnings Rating can be The chart indicates where analysts predict the stock price will be within
calculated for Tmc Life Sciences Berhad. The average Earnings the next 12 months, as compared to the current price.
Rating for its Health Facilities & Svcs industry is 4.0 and the FTSE
BURSA MALAYSIA COMPOSITE index average is 5.8. 12-Month Price Target
Mean (MYR) --
- There have been no upward or downward broker recommendation
High --
changes for Tmc Life Sciences Berhad over the past 120 days.
Data is not available Low --
Target vs. Current --
# of Analysts --
Current Price Price Target

(MYR)
Page 3 of 11
EARNINGS PER SHARE

Actuals Estimates
Earnings per share (EPS) is calculated Quarterly -- --

by dividing a company's earnings by the Mean -- --
number of shares outstanding. Analysts Quarterly data is not available
tend to interpret a pattern of increasing High -- --
earnings as a sign of strength and flat Low -- --
or falling earnings as a sign of
# of Analysts -- --
weakness.
The charts provide a comparison NA NA NA NA

between a company's actual and
estimated EPS, including the high and Actuals Estimates
low forecasts.
Annual -- --
Mean -- --
Annual data is not available
High -- --
Low -- --
# of Analysts -- --
NA NA NA NA
MEAN ESTIMATE TREND ANALYST RECOMMENDATIONS

Q Q Y Y Price I/B/E/S Mean: NA (0 Analysts)
-- -- -- -- Target
Current -- -- -- -- --
Strong Buy 0
30 Days Ago -- -- -- -- -- Buy 0
90 Days Ago -- -- -- -- -- Hold 0
% Change (90 Days) -- -- -- -- --
Sell 0
Current Fiscal Year End: --
Next Expected Report Date: -- Strong Sell 0
EARNINGS SURPRISES
Comparing a company's actual earnings to the mean expectation of Surprise Detail (Last 6 Periods)
analysts results in a difference referred to as a 'positive' or 'negative'
surprise. Research has shown that when a company reports a Surprise Announce Period End Actual Mean Surprise
surprise, it is often followed by more of the same surprise type. Type Date Date EPS EPS (%)
Surprise Summary (Last 12 Quarters)
Surprise Type Amount Percent There are no earnings surprises during this time period.
Positive Quarters (> 2%) 0 --
Negative Quarters (< -2%) 0 --
In-Line Quarters (within 2%) 0 --
ANNUAL REVENUE
A pattern of increasing sales in Actuals Estimates
conjunction with a rising EPS may
influence a buy recommendation, while NA NA
flat or falling sales and faltering
earnings may explain a sell Mean -- --
recommendation. A rising EPS with flat Annual revenue data is not available High -- --
or falling sales may result from
increased cost efficiency and margins, Low -- --
rather than market expansion. This Forecasted Growth -- --
chart shows the sales forecast trend of # of Analysts -- --
all analysts and the highest and lowest
projections for the current and next NA NA NA NA
fiscal year.
Page 4 of 11
FUNDAMENTAL
NEUTRAL OUTLOOK: Fundamentals relatively Fundamental Score Averages
in-line with the market. Health Providers & Svcs. Group: 5.5 Mid Market Cap: 6.2
Q3 Q4 Q1 Q2
Fundamental Score Trend Peers 2020 2020 2021 2021 Current 3Y Trend
IHH 6 8 NR NR 5
Positive
TDM 5 2 NR NR 5
Neutral TMCLIFE 3 7 7 5 4
Negative KPJ 3 4 NR NR 3
Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2
2019 2020
FUNDAMENTAL INDICATORS
Profitability Debt Earnings Quality Dividend
(25% weight) (25% weight) (25% weight) (25% weight)
TDM
IHH
IHH
IHH
KPJ KPJ
TDM TMCLIF…
TMCLIF… TMCLIF…
KPJ
TDM
IHH
TMCLIF… TDM
KPJ
Revenue Growth -5.6% Current Ratio 2.6 Oper. Cash Yield 13.5% Dividend Growth -16.9%
For year over year For interim period For latest 12 months For year over year
ending 2020-06 ending 2021-03 ending 2020-06 ending 2020-06
Gross Margin 9.0% Debt-to-Capital 10.1% Accruals 14.7% Dividend Payout 18.4%
For latest 12 months For annual period For latest 12 months For latest 12 months
Return On Equity 2.1% Interest Funding 0.7% Days Sales In Inv. 26.2 Dividend Coverage 6.0
For interim period For interim period For annual period For annual period
Net Margin 8.7% Interest Coverage 30.1 Days Sales In Rec. 71.3 Current Div. Yield 0.3%
For latest 12 months For interim period For annual period For latest 12 months
HIGHLIGHTS
- The Fundamental Rating for Tmc Life Sciences Berhad declined - TMCLIFE's operating cash yield of 13.5% is substantially below the
significantly over the last quarter from 7 to 4. The average Health Providers & Svcs. industry group average of 158.6%.
Fundamental Rating for its Health Providers & Svcs. industry group is - Of the 9 firms within the Health Providers & Svcs. industry group, Tmc
5.4 and the FTSE BURSA MALAYSIA COMPOSITE index average is Life Sciences Berhad is among 5 companies that pay a dividend. The
6.0. stock's dividend yield is currently 0.3%.
- The company's net margin has been higher than its industry group
average for each of the past five years.
- The company's current ratio has been higher than its industry group
average for each of the past five years.
Page 5 of 11
RELATIVE VALUATION
NEGATIVE OUTLOOK: Multiples significantly Relative Valuation Score Averages
above the market or the stock's historic norms. Health Providers & Svcs. Group: 2.6 Mid Market Cap: 4.9
Relative Valuation Score Trend (4-Week Moving Avg) Peers -6M -3M -1M -1W Current 1Y Trend
Positive TDM NR NR NR 7 7
IHH 1 1 1 2 2
TMCLIFE 3 3 4 2 2
Negative
2018-08 2019-08 2020-08 2021-08
RELATIVE VALUATION INDICATORS

Price to Sales Trailing PE Forward PE
(50% weight) (25% weight) (25% weight)
TDM
KPJ
IHH
IHH IHH
TMCLIFE
TMCLIFE KPJ
KPJ
TDM TDM
TMCLIFE
Price to Sales 5.7 Trailing PE 55.1 Forward PE --

5-Yr Average 12.3 5-Yr Average 67.4 5-Yr Average --
Rel. to 5-Yr Avg. 54% Discount Rel. to 5-Yr Avg. 18% Discount Rel. to 5-Yr Avg. --
FBM KLCI Index 2.7 FBM KLCI Index 17.7 FBM KLCI Index 15.8
Rel. to FBM KLCI >100% Premium Rel. to FBM KLCI >100% Premium Rel. to FBM KLCI --
HIGHLIGHTS
- Tmc Life Sciences Berhad currently has a Relative Valuation Rating of - TMCLIFE's 5.7 Price to Sales multiple is currently at the low end of its
2 which is significantly below the FTSE BURSA MALAYSIA 5-year range (lowest 5.7 to highest 14.0).
COMPOSITE index average rating of 4.0. - TMCLIFE's Trailing P/E of 55.1 represents a 18% Discount to its 5-
- TMCLIFE is currently valued at a premium to the FTSE BURSA year average of 67.4.
MALAYSIA COMPOSITE index based on both Price to Sales ratio and
Trailing P/E.
Page 6 of 11
PRICE TO SALES TRAILING PE

The most recent week's close price divided by the revenue per share. The most recent week's close price divided by the sum of the four most
recently reported quarterly earnings.
Price to Sales: 5.7 Trailing PE: 55.1
5-Year Average: 12.3 5-Year Average: 67.4
FBM KLCI Index Average: 2.7 FBM KLCI Index Average: 17.7
Health Providers & Svcs. Group Average: 3.4 Health Providers & Svcs. Group Average: 58.7
15 >50
14 48
13 46
5-Yr Average
12 44
11 42
10 40
9 38
8 36
7 34
6 32
5 30
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
FORWARD PE FORWARD PEG

The most recent week's close price divided by the sum of the four The Forward P/E divided by the five-year forecasted growth rate.
upcoming quarterly consensus estimates.
Forward PE: -- Forward PEG: --
5-Year Average: -- 5-Year Average: --
FBM KLCI Index Average: 15.8 FBM KLCI Index Average: 0.8
Health Providers & Svcs. Group Average: 33.5 Health Providers & Svcs. Group Average: --
>50 >5.0
45 4.5
40 4.0
35 3.5
30 3.0
25 This valuation data is not available 2.5 This valuation data is not available
20 2.0
15 1.5
10 1.0
5 0.5
<0 <0.0
2017 2018 2019 2020 2021 2017 2018 2019 2020 2021
Page 7 of 11
RISK
POSITIVE OUTLOOK: Consistent return Risk Score Averages
patterns (low volatility). Health Providers & Svcs. Group: 6.8 Mid Market Cap: 7.4
Risk Score Trend (4-Week Moving Avg) Peers -6M -3M -1M -1W Current 1Y Trend
TMCLIFE 9 9 9 10 10
TDM 3 4 5 6 7
Negative
2018-08 2019-08 2020-08 2021-08
RISK INDICATORS
Magnitude of Returns Volatility Beta (1-year) Correlation
(25% weight) (25% weight) (25% weight) (25% weight)
IHH IHH
IHH
KPJ KPJ TMCLIF…
TDM
TMCLIF… TMCLIF…
IHH
TDM TDM KPJ TMCLIF…
TDM
KPJ
Daily Returns (Last 90 Days) Standard Deviation Beta vs. FBM KLCI -0.02 Correlation vs. FBM KLCI
Best 6.9% Last 90 Days 2.06 Positive Days Only -0.28 Last 90 Days 23%
Worst -6.3% Last 60 Months 6.93 Negative Days Only 0.18 Last 60 Months 45%
Monthly Returns (Last 60 Months) Intra-Day Swing (Last 90 Days) Beta vs. Group 0.42 Correlation vs. Group
Best 22.9% Average 2.8% Positive Days Only 0.22 Last 90 Days 36%
Worst -27.6% Largest 7.5% Negative Days Only 0.88 Last 60 Months 60%
HIGHLIGHTS RISK ANALYSIS

- Tmc Life Sciences Berhad currently has a Risk Rating of 10 Last 90 Days Last 60 Months
while the FTSE BURSA MALAYSIA COMPOSITE index has an Best Worst # # Largest Best Worst
average rating of 9. Daily Daily Days Days Intra-Day Monthly Monthly
- On days when the market is up, TMCLIFE shares typically Peers Return Return Up Down Swing Return Return
decrease. Furthermore, on days when the market is down, the TMCLIFE 6.9% -6.3% 19 28 7.5% 22.9% -27.6%
shares tend to decline less than the FTSE BURSA MALAYSIA
COMPOSITE index. IHH 3.2% -2.8% 34 23 5.1% 13.1% -11.0%
- In the short term, TMCLIFE has shown average correlation (>= KPJ 3.9% -2.7% 25 19 9.0% 12.4% -9.6%
0.2 and < 0.4) with the FTSE BURSA MALAYSIA COMPOSITE
index. The stock has, however, shown high correlation (>= 0.4) TDM 2.2% -4.2% 20 21 6.4% 95.4% -41.7%
with the market in the long term.
FBM KLCI 1.4% -1.4% 27 34 1.6% 6.8% -8.9%
- Over the last 90 days, TMCLIFE shares have been more
volatile than the overall market, as the stock's daily price
fluctuations have exceeded that of 86% of FTSE BURSA
MALAYSIA COMPOSITE index firms.
Page 8 of 11
PRICE MOMENTUM Currency in MYR
NEGATIVE OUTLOOK: Weak recent price Price Momentum Score Averages

performance or entering historically poor Health Providers & Svcs. Group: 8.0 Mid Market Cap: 5.5
seasonal period. Healthcare Services & Equip. Sector: 6.0 FBM KLCI Index: 5.9
Price Momentum Score Trend (4-Week Moving Avg) Peers -6M -3M -1M -1W Current 1Y Trend
Positive KPJ 9 8 8 10 10
IHH 3 5 9 9 9
Neutral TDM 6 6 3 4 5
TMCLIFE 9 2 3 4 3
Negative
2018-08 2019-08 2020-08 2021-08
PRICE MOMENTUM INDICATORS

Relative Strength Seasonality
(70% weight) (30% weight)
IHH
TMCLIFE
KPJ
KPJ
TDM IHH
TDM
TMCLIFE
Relative Strength Indicator (Scale from 1 to 100) Average Monthly Return (Last 10 Years)
TMCLIFE Industry Avg Aug Sep Oct
Last 1 Month 48 53 Company Avg -3.0% 6.3% 1.4%
Last 3 Months 47 52 Industry Avg 0.4% 0.3% 3.2%
Last 6 Months 48 52 Industry Rank 11 of 49 27 of 50 16 of 50
PRICE PERFORMANCE
Daily close prices are used to calculate the TMCLIFE TMCLIFE FBM KLCI
performance of the stock as compared to a
FBM KLCI Close Price (2021-08-24) 0.61 1,553
relevant index over five time periods.
52-Week High 0.82 1,685
0%
1-Week 52-Week Low 0.47 1,461
2%
-0.8% - Tmc Life Sciences Berhad has a Price Momentum Rating of 3,

1-Month
2% which is significantly below the FTSE BURSA MALAYSIA
COMPOSITE index average rating of 5.9.
-4.7%
3-Month - On 2021-08-24, TMCLIFE closed at 0.61, 25.6% below its 52-
-1.2% week high and 29.8% above its 52-week low.
-7.6% - TMCLIFE shares are currently trading 1.1% below their 50-day
YTD moving average of 0.62, and 9.0% below their 200-day moving
-4.5%
average of 0.67.
19.6%
1-Year
-1%
Page 9 of 11
DETAILED STOCK REPORT TIPS Mean Estimate Trend

The mean estimates show how the consensus has changed over the past 30 days
The Stock Report from Refinitiv is a comprehensive, company-specific analysis that and 90 days for the upcoming two quarters (when available) and two years. The
includes a proprietary Stock Rating along with underlying component indicators and percentage change is calculated for the company as a means for comparison by
supportive data elements. The report is updated daily, although some of the data measuring the difference between the current consensus estimate and that of 90
elements and the ratings are updated weekly. days ago.
Average Score Analyst Recommendations
The Stock Reports Plus Average Score combines a quantitative analysis of five The I/B/E/S Mean is the average recommendation of all analysts covering the stock,
widely-used investment decision making tools - Earnings, Fundamental, Relative as provided by I/B/E/S, the Institutional Brokers Estimate System, from Refinitiv.
Valuation, Risk, and Price Momentum. First, a simple average of the five underlying The recommendations are presented on a five-point standardized scale: strong buy,
component ratings is calculated. Then, a normal distribution is used to rank each buy, hold, reduce, and sell.
stock across the market on a scale of 1 to 10, with 10 being most favorable. A
score of 8 to 10 is considered positive, 4 to 7 is neutral, and 1 to 3 is negative. Earnings Surprises
These five factors may be evaluated differently using alternative methodologies, ● The surprise summary includes the total number of time periods (and
and the importance of individual factors varies across industry groups, market percentage) in the last 12 quarters (quarterly) or last 4 years (annual) in which
capitalization and investment styles. Additional criteria should always be used to earnings surprises were positive, negative, or in-line. In order to be recognized
evaluate a stock. as a positive or negative surprise, the percent must be greater than 2% above or
2% below the consensus, respectively.
A company must have sufficient data available for at least three of the five ● The surprise detail section includes a listing of the company's quarterly earnings
component indicators in order to receive an overall Average Score. Approximately reported for the most recent 6 periods (quarters or years). The consensus
85% of the stocks within the coverage universe meet the criteria to generate a analyst estimate is provided to determine if the actual earnings report
score. represented a positive surprise, negative surprise, or in-line result.
Indicator Components Fundamental
The five indicators that comprise the stock rating are displayed. Like the stock The Fundamental Rating is based on a combination of four fundamental component
rating, the component rating scale is 1 to 10, with 10 being best. A company will factors: profitability, debt, earnings quality, and dividend. Companies that do not
receive an ‘NR’ for No Rating if the required data elements or criteria are not met. A pay a dividend are not penalized. Each factor is equally weighted. Then, equal
detailed section for each component is included in the report. deciles are used to rank each stock across the market on a scale of 1 to 10, with 10
being most favorable. A stock needs to have at least two of the four fundamental
Indicator Trends factors present in order to receive a score.
Within each component section, historical score trends are displayed, typically using
a 4-week moving average over a timeframe of the past three years. The dotted ● Profitability is comprised of four data elements.
orange line indicates the average of the scores over those three years. The most - Revenue Growth: (Net Sales – Previous Net Sales) / Previous Net Sales
recent occurrences of the best and worst scores are also displayed on the chart in - Gross Margin: Gross Profit / Net Sales
grey boxes to put the current score into historical context. - Return on Equity: Net Income / Total Equity
- Net Margin: Net Profit / Net Sales
Next to the trend chart for the company, current score averages are included, along ● Debt is comprised of four data elements.
with peer company comparisons of values from 6 months ago, 3 months ago, 1 - Current Ratio: Current Assets / Current Liabilities
month ago, the most recent value from 1 week ago, and the current score. The four - Debt-to-Capital: Total Debt / Total Capital
closest industry peers are presented based on similar market capitalization. - Interest Funding: (Interest Expense on Debt + Preferred Cash Dividends) /
Funds from Operations
Peer Analysis - Interest Coverage: Earnings before Interest and Taxes / (Interest Expense on
● The Refinitiv Business Classification (TRBC) schema is used for industry Debt + Preferred Cash Dividends)
comparisons. It is designed to track and display the primary business of a ● Earnings Quality is comprised of four data elements.
corporation by grouping together correlated companies that offer products and - Operating Cash Yield: (Operating Cash Flow – Net Income) / Net Income
services into similar end markets. The system includes 10 Economic Sectors, 28 - Accruals: (Net Income – Operating Cash Flow – Investing Cash Flow) /
Business Sectors, 54 Industry Groups, and 136 Industries. Average Net Operating Assets
● The Peer Analysis section of the report compares the company to its ten closest - Days Sales in Inventory: 365 / (Cost of Goods Sold / Inventory)
peers. The peers are selected from the industry based on similar market - Days Sales in Receivables: 365 / (Net Sales / Receivables)
capitalization. The peer listing may have fewer than ten companies if there are ● Dividend is comprised of four data elements. The company must have a current
fewer than ten companies within that industry classification. dividend yield.
- Dividend Growth Rate: (Dividends per Share – Previous Dividends per Share)
Highlights / Previous Dividends per Share
The automated text-generation system from Refinitiv creates highlights - Dividend Payout: Dividends per Share / Earnings per Share
summarizing the most noteworthy data. The bullets will vary by company and will - Dividend Coverage: Funds from Operations / Cash Dividends
change from week to week as different criteria are met. - Dividend Yield: Annual Dividends per Share / Current Market Price per Share
Earnings Indicator Trend

The Earnings Rating is based on a combination of three factors: earnings surprise, The fundamental indicator trend displays either quarterly scores over the past three
estimate revision, and recommendation changes. Each factor is equally weighted. years or annual scores over the past six years, depending on the reporting periods
Then, equal deciles are used to rank each stock across the market on a scale of 1 for the country. The best and worst scores can be easily determined from the
to 10, with 10 being most favorable. A stock needs to have at least two of the three values shown on the chart for each quarter or year.
earnings factors in order to receive a score.
Relative Valuation
● Earnings Surprises - The number of positive and negative surprises within the The Relative Valuation Rating is based on a combination of three component
last 4 periods (quarters or years). factors: Price to Sales (50% weight), Trailing P/E (25% weight), and Forward P/E
● Estimate Revisions - The number of up and down revisions and the average (25% weight). After the weightings are considered to combine individual factors,
percentage change of those revisions within a 4 week period. equal deciles are used to rank each stock across the market on a scale of 1 to 10,
● Recommendation Changes - The number of broker upgrades and downgrades in with 10 being most favorable. These common valuation metrics are evaluated
the last 120 days. against the overall market, the index, and the company's own historic 5-year
averages. A stock needs to have at least one of the three relative valuation factors
Price Target in order to receive a score.
The price target is based on the predictions of analysts covering the stock and
shows the high, low and mean price expected within the next 12 months. ● Price to Sales: Close Price / (Sales for 4 Quarters or 1 Year / Shares
Outstanding)
Earnings Per Share ● Trailing P/E: Close Price / Most Recent 4 Quarters or 1 Year of Earnings
The quarterly and annual earnings per share are presented when available, along ● Forward P/E: Close Price / Upcoming 4 Quarters or 1 Year of Earnings
with the mean, high and low. Quarterly data is displayed for the past 4 quarters
(actual) and the next 2 quarters (estimated). Annual data is displayed for the past 2
years (actual) and the next 2 years (estimated).
Page 10 of 11
Valuation Averages
Negative values are excluded when calculating the averages. A maximum value of
100 is placed on Trailing P/E and Forward P/E, a maximum value of 5 is placed on
Forward PEG, and a maximum value of 20 is placed on Price to Sales when
calculating the averages. Higher values are rounded down to the maximum for the
averages.
Valuation Multiples
The valuation multiples provide the Trailing P/E, Forward P/E, Forward PEG, and
Price to Sales for the company and the S&P 500 index average. In addition, a
comparison of the current company’s values to its 5-year average and an industry
average are presented. A discount occurs when the company’s ratio is valued
more favorably (lower) than that to which it is compared.
Risk
The Risk Rating displays stocks on a scale of 1 to 10 with 10 being awarded to the
least risky stocks. It is derived by looking at a series of long-term (5-year) and
short-term (90-day) stock performance measures including volatility, magnitude of
returns, beta, and correlation. Each factor is equally weighted. Then, equal deciles
are used to rank each stock across the market. A stock needs to have at least two
of the four risk factors in order to receive a score.
● Magnitude of Returns – The best / worst daily returns in the past 90 days and the
best / worst monthly returns in the past 60 months.
● Volatility – The standard deviation of the stock price over the last 90 days and
last 60 months, along with the average and largest intra-day stock swing.
● Beta – Measures the tendency of a security’s returns to respond to swings in the
market, based on the beta of the company versus the relevant index.
● Correlation – Determines how closely the returns of the stock and the relevant
index move together, measured over the last 90 days and last 60 months.
Risk Analysis
Price analysis for the company and the relevant index is provided over two time
periods. Daily analysis is provided for the last 90 days, whereas monthly statistics
are used for the last 60 months.
Price Momentum
The Price Momentum Rating is based on a combination of two technical
performance factors: relative strength (70% weight) and seasonality (30% weight).
After the weightings are considered to combine individual factors, equal deciles are
used to rank each stock across the market on a scale of 1 to 10, with 10 being most
favorable. A stock needs to have data for the relative strength factor in order to
receive a score.
● Relative Strength – The relative strength of the company for the last 1 month, 3
months, and 6 months on a scale of 1 to 100.
● Seasonality – The average monthly return (price performance) for the current
month and next 2 months for the company and industry, over the past 10 years.
A lower industry rank indicates a higher return.
Price Performance
Daily close prices are used to calculate the price performance of the stock. The
performance of the relevant index is also displayed as a means of comparison.
DISCLAIMER
© 2020 Refinitiv. Republication or redistribution of Refinitiv content, including by
framing or similar means, is prohibited without the prior written consent of Refinitiv.
All information in this report is assumed to be accurate to the best of our ability.
Refinitiv is not liable for any errors or delays in Refinitiv content, or for any actions
taken in reliance on such content.
Any forward-looking statements included in the Refinitiv content are based on

certain assumptions and are subject to a number of risks and uncertainties that
could cause actual results to differ materially from current expectations. There is no
assurance that any forward-looking statements will materialize.
The content in this Refinitiv report does not constitute investment advice or a
recommendation to buy or sell securities of any kind. Past performance is not a
guarantee of future results. Investors should consider this report as only a single
factor when making an investment decision.
Page 11 of 11

Average Score: TMC Life Sciences Berhad (Tmclife-Ku)

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Average Score: TMC Life Sciences Berhad (Tmclife-Ku)

Uploaded by

Copyright:

Available Formats

TMC LIFE SCIENCES BERHAD (TMCLIFE-KU)

HIGHLIGHTS I/B/E/S MEAN

PRICE AND VOLUME CHARTS

Earnings Fundamental Relative Valuation Risk Price Momentum

PEER ANALYSIS Currency in MYR

PRICE MOMENTUM VALUATION FUNDAMENTAL ANALYSTS

EARNINGS Currency in MYR

TDM TDM TDM

Last 4 Quarters Last 4 Weeks Last 120 Days

HIGHLIGHTS PRICE TARGET

Current Price Price Target

EARNINGS PER SHARE

Earnings per share (EPS) is calculated Quarterly -- --

The charts provide a comparison NA NA NA NA

MEAN ESTIMATE TREND ANALYST RECOMMENDATIONS

RELATIVE VALUATION INDICATORS

Price to Sales 5.7 Trailing PE 55.1 Forward PE --

PRICE TO SALES TRAILING PE

FORWARD PE FORWARD PEG

HIGHLIGHTS RISK ANALYSIS

PRICE MOMENTUM Currency in MYR

NEGATIVE OUTLOOK: Weak recent price Price Momentum Score Averages

PRICE MOMENTUM INDICATORS

-0.8% - Tmc Life Sciences Berhad has a Price Momentum Rating of 3,

DETAILED STOCK REPORT TIPS Mean Estimate Trend

Earnings Indicator Trend

Any forward-looking statements included in the Refinitiv content are based on

You might also like